2026 Q1 -tulosraportti
97 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.
Welcome to the club, see that you have taken my hint literally👏👏 I have (with good AI assistance, crazy what one can achieve with it☝️) conducted a rather in-depth due diligence of Egetis - both on the company in isolation, and also held up against comparable biotech companies in Sweden - and - in Europe generally. Yes, agreed☝️ For many, it will be considered a lottery ticket to put their liquid assets into Egetis, admitted & accepted. It is simply the case, in my view, that Egetis is such a sufficiently asymmetric bet, (the relationship between current company value and possible future potential) that if one is otherwise comfortable trading Start-Up’s, Small-Cap, You-Name-Them, then a thorough study of the company will reveal a really interesting case to have in one's portfolio. No guarantees are given that it will be a party, but should music arise - then all partygoers will very quickly start jumping in sync. Engagement in the financial markets has NOTHING to do with 'KNOWING', but rather EVERYTHING to do with assessing PROBABILITY and RISK. I have taken the bet that Egetis should account for 13-15% of my portfolio, (loooong story how I arrived at those numbers) before the FDA decision falls at the end of September. I am aware that there is a RISK that I can lose the entire position - the FDA’s decision on the submitted NDA is instrumental for the company's continued existence. Ladies & Gentlemen☝️ Bet’s please☝️☝️
·3 päivää sitten · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.- ·31.7.Great article about egetis, those of you who are interested, read. https://investeramera.se/analyser/egetis-therapeutics-rakna-ner-till-28-september
·31.7.That was indeed a really big position for sale…- ·30.7.The Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️
Got a good entry thanks to having read your posts a few days ago. Thanks for sharing👌🏼 @Teknikeren
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
97 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.Welcome to the club, see that you have taken my hint literally👏👏 I have (with good AI assistance, crazy what one can achieve with it☝️) conducted a rather in-depth due diligence of Egetis - both on the company in isolation, and also held up against comparable biotech companies in Sweden - and - in Europe generally. Yes, agreed☝️ For many, it will be considered a lottery ticket to put their liquid assets into Egetis, admitted & accepted. It is simply the case, in my view, that Egetis is such a sufficiently asymmetric bet, (the relationship between current company value and possible future potential) that if one is otherwise comfortable trading Start-Up’s, Small-Cap, You-Name-Them, then a thorough study of the company will reveal a really interesting case to have in one's portfolio. No guarantees are given that it will be a party, but should music arise - then all partygoers will very quickly start jumping in sync. Engagement in the financial markets has NOTHING to do with 'KNOWING', but rather EVERYTHING to do with assessing PROBABILITY and RISK. I have taken the bet that Egetis should account for 13-15% of my portfolio, (loooong story how I arrived at those numbers) before the FDA decision falls at the end of September. I am aware that there is a RISK that I can lose the entire position - the FDA’s decision on the submitted NDA is instrumental for the company's continued existence. Ladies & Gentlemen☝️ Bet’s please☝️☝️
- ·3 päivää sitten · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.
- ·31.7.Great article about egetis, those of you who are interested, read. https://investeramera.se/analyser/egetis-therapeutics-rakna-ner-till-28-september
- ·31.7.That was indeed a really big position for sale…
- ·30.7.The Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️Got a good entry thanks to having read your posts a few days ago. Thanks for sharing👌🏼 @Teknikeren
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
97 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.Welcome to the club, see that you have taken my hint literally👏👏 I have (with good AI assistance, crazy what one can achieve with it☝️) conducted a rather in-depth due diligence of Egetis - both on the company in isolation, and also held up against comparable biotech companies in Sweden - and - in Europe generally. Yes, agreed☝️ For many, it will be considered a lottery ticket to put their liquid assets into Egetis, admitted & accepted. It is simply the case, in my view, that Egetis is such a sufficiently asymmetric bet, (the relationship between current company value and possible future potential) that if one is otherwise comfortable trading Start-Up’s, Small-Cap, You-Name-Them, then a thorough study of the company will reveal a really interesting case to have in one's portfolio. No guarantees are given that it will be a party, but should music arise - then all partygoers will very quickly start jumping in sync. Engagement in the financial markets has NOTHING to do with 'KNOWING', but rather EVERYTHING to do with assessing PROBABILITY and RISK. I have taken the bet that Egetis should account for 13-15% of my portfolio, (loooong story how I arrived at those numbers) before the FDA decision falls at the end of September. I am aware that there is a RISK that I can lose the entire position - the FDA’s decision on the submitted NDA is instrumental for the company's continued existence. Ladies & Gentlemen☝️ Bet’s please☝️☝️
- ·3 päivää sitten · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.
- ·31.7.Great article about egetis, those of you who are interested, read. https://investeramera.se/analyser/egetis-therapeutics-rakna-ner-till-28-september
- ·31.7.That was indeed a really big position for sale…
- ·30.7.The Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️Got a good entry thanks to having read your posts a few days ago. Thanks for sharing👌🏼 @Teknikeren
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt